NovoCure

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

CEO

Ashley Cordova

CEOAshley Cordova

Employees

1,488

Employees1,488

Headquarters

St. Helier, Jersey

HeadquartersSt. Helier, Jersey

Founded

2000

Founded2000

Employees

1,488

Employees1,488

NVCR Key Statistics

Market cap

1.41B

Market cap1.41B

Price-Earnings ratio

-8.15

Price-Earnings ratio-8.15

Dividend yield

—

Dividend yield—

Average volume

1.49M

Average volume1.49M

High today

$13.00

High today$13.00

Low today

$12.56

Low today$12.56

Open price

$12.88

Open price$12.88

Volume

1.55M

Volume1.55M

52 Week high

$34.13

52 Week high$34.13

52 Week low

$10.87

52 Week low$10.87

NVCR News

Simply Wall St 1d

NovoCure Gains Japan Approval For Optune Lua® In NSCLC Treatment Combo

recently secured approval for its Optune Lua® device in Japan, a milestone for the company’s TTFields therapy that targets non-small cell lung cancer. This deve...

TipRanks 1d

NovoCure Gains Approval for Optune Lua in Japan

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 1d

Novocure announces Japan MHLW approval for Optune Lua

Novocure (NVCR) announced that Japan’s Ministry of Health, Labour and Welfare approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for the treatmen...

Analyst ratings

63%

of 8 ratings

Buy

62.5%

Hold

37.5%

Sell

More NVCR News

Simply Wall St 3d

How Investors May Respond To NovoCure FDA Approval of Optune Lua for Lung Cancer

Earlier this month, NovoCure announced that its Optune Lua device received FDA approval for the treatment of non-small cell lung cancer, marking a significant m...

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.